Qualigen Therapeutics (NASDAQ:AIXC) Stock Price Down 3.4% – What’s Next?

Shares of Qualigen Therapeutics, Inc. (NASDAQ:AIXC) dropped 3.4% during mid-day trading on Wednesday . The stock traded as low as $0.7583 and last traded at $0.7711. 17,246 shares changed hands during trading, a decline of 54% from the average daily volume of 37,690 shares. The stock had previously closed at $0.7980.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Qualigen Therapeutics in a research report on Tuesday, July 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Qualigen Therapeutics Stock Performance

The stock has a market cap of $15.60 million, a P/E ratio of -0.12 and a beta of 0.53. The company’s 50 day moving average is $1.08.

Qualigen Therapeutics (NASDAQ:AIXC) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.